跳至主要内容
临床试验/NL-OMON42537
NL-OMON42537已完成3 期

A multi-center, Randomized, double-blind, placebo-controlled study to Evaluate the Safety and efficacy of a single oral dose of vanoxerine for The conversion Of subjects with REcent onset atrial fibrillation or flutter to normal Sinus Rhythm - RESTORE SR

aguna Pharmaceuticals, Inc0 个研究点目标入组 16 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Onset of Atrial fibrillation/Atrial Flutter within the 7 calendar days preceding randomisation, based on symptoms. AF/AFL documented by ECG during the screening period and immediately prior to study drug administration. (see protocol page 30)

排除标准

  • See protocol page 30 and 31

研究者

发起方
aguna Pharmaceuticals, Inc

相似试验

进行中(未招募)
不适用
A sleep laboratory study to investigate the safety and efficacy of the rotigotine skin patch in subjects with Restless Legs Syndrome and End-Stage Renal Disease requiring hemodialysisRestless Legs Syndrome in patients with End Stage Renal Disease (ESRD)MedDRA version: 14.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2011-003486-15-DECB BIOSCIENCES GmbH48
进行中(未招募)
不适用
Study designed to demonstrate the efficacy and safety of Certolizumab pegol in combination with Methotrexate in the treatment of subjects suffering from early, progressive active rheumatoid arthritis.Early active rheumatoid arthritisMedDRA version: 17.1Level: LLTClassification code 10003268Term: Arthritis rheumatoidSystem Organ Class: 100000004859
EUCTR2011-001729-25-DECB Pharma SA800
进行中(未招募)
不适用
Effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failureType 2 Diabetes. Heart failure (NYHA class I-III).MedDRA version: 13.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 13.1Level: LLTClassification code 10064081Term: Heart failure NYHA class IIISystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 13.1Level: LLTClassification code 10064079Term: Heart failure NYHA class ISystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 13.1Level: LLTClassification code 10064080Term: Heart failure NYHA class IISystem Organ Class: 10007541 - Cardiac disorders
EUCTR2008-005012-41-LVovartis Pharma Services AG490
进行中(未招募)
不适用
A multi-center, randomized, double-blind, placebo-controlled, crossover study in women with irritable bowel syndrome to evaluate feasibility and reproducibility of barostat assessments of colorectal sensation during colorectal distention and its pharmacological modulation using octreotideIrritable Bowel SyndromMedDRA version: 9.1Level: PTClassification code 10023003Term: Irritable bowel syndrome
EUCTR2007-004994-25-SEovartis Pharma Services AG46
进行中(未招募)
1 期
A multi-center, randomized, double-blind, placebo-controlled phase III trial omparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL) - MAI
EUCTR2006-005520-16-SKF. Hoffmann-La Roche Ltd1,060